Veradermics VDPHL01: why isn’t anyone talking about it? Treatment 12/14/2024
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
View this post in the Community →
Similar Community Posts Join
5 / 26 resultscommunity 6 months before and after pics: VDPHL01 (oral minoxidil)
A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.
community Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community VDPHL-01 is Overrated and Ridiculous. This is just Oral Minoxidil.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
Related Research
5 / 5 resultsresearch Universal Dermatology: Bridging Gaps in Skin Health
Inclusive dermatology aims to provide personalized skin care for all by addressing diverse needs and disparities.
research Exploring Novel Management Options for Alopecia Areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research Patient Perspectives Regarding Artificial Intelligence-Driven Trichoscopy for Alopecia Evaluation
Patients found AI helpful for alopecia diagnosis but want it to support, not replace, doctors.
research A Decade of Autologous Micrografting Technology in Hair Restoration: A Review of Clinical Evidence and the Evolving Landscape of Regenerative Treatments
Autologous Micrografting Technology effectively improves hair growth and is a safe, promising option for hair restoration.
research Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.